Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 127

1.

Impact of aprepitant on emesis control, dose intensity, and recurrence-free survival in a population-based cohort of head and neck cancer patients receiving high-dose cisplatin chemotherapy.

Makarenko S, Dranitsaris G, Peixoto RD, Ruan JY, Cheung WY.

J Community Support Oncol. 2014 Nov;12(11):394-400. doi: 10.12788/jcso.0085.

PMID:
25856012
2.

Management of patients with Cushing's disease: a Canadian cost of illness analysis.

Uum SV, Hurry M, Petrella R, Koch C, Dranitsaris G, Lacroix A.

J Popul Ther Clin Pharmacol. 2014;21(3):e508-17. Epub 2014 Nov 28.

3.

Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting.

Dranitsaris G, Gluck S, Faria C, Cox D, Rugo H.

Clin Ther. 2015 Jan 1;37(1):134-44. doi: 10.1016/j.clinthera.2014.10.023. Epub 2014 Nov 26.

PMID:
25433768
4.

Abraxane® versus Taxol® for patients with advanced breast cancer: A prospective time and motion analysis from a Chinese health care perspective.

Dranitsaris G, Yu B, Wang L, Sun W, Zhou Y, King J, Kaura S, Zhang A, Yuan P.

J Oncol Pharm Pract. 2014 Oct 14. pii: 1078155214556008. [Epub ahead of print]

PMID:
25316611
5.

Health Technology Assessment of Cancer Drugs in Canada, the United Kingdom and Australia: Should the United States Take Notice?

Dranitsaris G, Papadopoulos G.

Appl Health Econ Health Policy. 2014 Oct 2. [Epub ahead of print]

PMID:
25274258
6.

What is a new drug worth? An innovative model for performance-based pricing.

Dranitsaris G, Dorward K, Owens RC, Schipper H.

Eur J Cancer Care (Engl). 2015 May;24(3):313-20. doi: 10.1111/ecc.12240. Epub 2014 Sep 25.

PMID:
25256668
7.

Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine.

Dranitsaris G, Lacouture ME.

Breast Cancer Res Treat. 2014 Oct;147(3):631-8. doi: 10.1007/s10549-014-3126-0. Epub 2014 Sep 13.

8.

Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients.

Belum VR, Rosen AC, Jaimes N, Dranitsaris G, Pulitzer MP, Busam KJ, Marghoob AA, Carvajal RD, Chapman PB, Lacouture ME.

Cancer. 2015 Jan 1;121(1):60-8. doi: 10.1002/cncr.28980. Epub 2014 Sep 3.

PMID:
25186461
9.

A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.

Addison CL, Bouganim N, Hilton J, Vandermeer L, Dent S, Amir E, Hopkins S, Kuchuk I, Segal R, Song X, Gertler S, Mazzarello S, Dranitsaris G, Ooi D, Pond G, Clemons M.

Breast Cancer Res Treat. 2014 Apr;144(3):615-24. doi: 10.1007/s10549-014-2906-x. Epub 2014 Mar 18.

10.
11.

Risk prediction models for chemotherapy-induced nausea and vomiting: almost ready for prime time?

Dranitsaris G, Clemons M.

Support Care Cancer. 2014 Apr;22(4):863-4. doi: 10.1007/s00520-014-2134-2. Epub 2014 Jan 29. No abstract available.

PMID:
24474600
12.

Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and cost.

Dranitsaris G, Ellis AK.

J Eval Clin Pract. 2014 Jun;20(3):225-38. doi: 10.1111/jep.12112. Epub 2014 Jan 21. Review.

PMID:
24444390
13.

Preference weights for chemotherapy side effects from the perspective of women with breast cancer.

Kuchuk I, Bouganim N, Beusterien K, Grinspan J, Vandermeer L, Gertler S, Dent SF, Song X, Segal R, Mazzarello S, Crawley F, Dranitsaris G, Clemons M.

Breast Cancer Res Treat. 2013 Nov;142(1):101-7. doi: 10.1007/s10549-013-2727-3. Epub 2013 Oct 16.

PMID:
24129976
14.

Are community pharmacists equipped to ensure the safe use of oral anticancer therapy in the community setting? Results of a cross-country survey of community pharmacists in Canada.

Abbott R, Edwards S, Whelan M, Edwards J, Dranitsaris G.

J Oncol Pharm Pract. 2014 Feb;20(1):29-39. doi: 10.1177/1078155213504975. Epub 2013 Oct 8.

PMID:
24103897
15.

Outcomes assessment of a pharmacist-directed seamless care program in an ambulatory oncology clinic.

Edwards SJ, Abbott R, Edwards J, LeBlanc M, Dranitsaris G, Donnan J, Laing K, Whelan MA, MacKinnon NJ.

J Pharm Pract. 2014 Feb;27(1):46-52. doi: 10.1177/0897190013504954. Epub 2013 Sep 24.

PMID:
24065784
16.

Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.

Dranitsaris G, Schmitz S, Broom RJ.

J Cancer Res Clin Oncol. 2013 Nov;139(11):1917-26. doi: 10.1007/s00432-013-1510-5. Epub 2013 Sep 14. Review.

PMID:
24037486
17.

Full-dose chemotherapy in early stage breast cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropenia.

Chiarotto JA, Dranitsaris G.

Support Care Cancer. 2013 Oct;21(10):2727-31. doi: 10.1007/s00520-013-1851-2. Epub 2013 May 26.

PMID:
23708859
18.

Clinical outcomes of women with metastatic breast cancer treated with nab-paclitaxel: experience from a single academic cancer centre.

Dent S, Fraser J, Graham N, Campbell M, Hopkins S, Dranitsaris G.

Curr Oncol. 2013 Feb;20(1):24-9. doi: 10.3747/co.20.1202.

19.

Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting.

Bouganim N, Dranitsaris G, Hopkins S, Vandermeer L, Godbout L, Dent S, Wheatley-Price P, Milano C, Clemons M.

Curr Oncol. 2012 Dec;19(6):e414-21. doi: 10.3747/co.19.1074.

20.

Clinical trial design in biosimilar drug development.

Dranitsaris G, Dorward K, Hatzimichael E, Amir E.

Invest New Drugs. 2013 Apr;31(2):479-87. doi: 10.1007/s10637-012-9899-2. Epub 2012 Nov 17. Review.

PMID:
23161336
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk